Cipla is currently trading at Rs. 325.90, up by 8.50 points or 2.68% from its previous closing of Rs. 317.40 on the BSE.
The scrip opened at Rs. 319.00 and has touched a high and low of Rs. 329.00 and Rs. 318.80 respectively. So far 207655 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 359.00 on 07-Feb-2012 and a 52 week low of Rs. 273.60 on 06-Sep-2011.
Last one week high and low of the scrip stood at Rs. 329.00 and Rs. 309.20 respectively. The current market cap of the company is Rs. 26175.24 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 33.27% and 29.84% respectively.
Cipla has slashes its prices on three key cancer medicines by taking advantage of the economies of scale it has managed to get on the product. The entity has significantly dropped its prices on generic Sorafenib, used in advanced kidney cancer, from Rs 27,950 to Rs 6,840.
Sorafenib is the drug on which the Patent Office recently issued a compulsory licence allowing Natco to make a generic copy of this drug, on the payment of a royalty to the innovator company, Bayer. Natco had pegged its price at about Rs 8,900, while Bayer’s price on its branded Sorafenib (Nexavar) is Rs 2.8 lakh.
The company has also reduced its prices on lung cancer drug Gestinib by 60%. Retail prices have come down from Rs 10,200 to Rs 4,250. The original drug is made by Astra Zeneca under the name Iressa.
The third drug that Cipla is dropping the prices is on brain tumour drug Temozolamide in three strengths. Schering makes the original drug. On the 20-mg pack of five, Cipla has been brought down the prices from Rs 1,875 to Rs 480; on the 100-mg strength prices are down from Rs 8,900 to Rs 2,400 and on the 250 mg it is down from Rs 20,250 to Rs 5,000.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1804.80 |
Dr. Reddys Lab | 1176.25 |
Cipla | 1541.00 |
Lupin | 2067.40 |
Zydus Lifesciences | 887.95 |
View more.. |